Sabatini Brent 4
4 · Vir Biotechnology, Inc. · Filed Feb 24, 2026
Insider Transaction Report
Form 4
Sabatini Brent
SVP, Chief Accounting Officer
Transactions
- Award
Common Stock
[F1]2026-02-22+25,000→ 72,872 total - Sale
Common Stock
[F2]2026-02-23$7.45/sh−1,829$13,631→ 71,043 total - Award
Stock Option (Right to Buy)
[F3]2026-02-22+50,000→ 50,000 totalExercise: $7.56Exp: 2036-02-21→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
- [F2]Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.v
- [F3]25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter.
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact|2026-02-24